

Role of CD26/dipeptidyl peptidase IV in human T cell activation and function

Kei Ohnuma¹, Nozomu Takahashi¹, Tadanori Yamochi¹, Osamu Hosono¹, Nam H. Dang², Chikao Morimoto¹

¹*Division of Clinical Immunology, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan,* ²*Department of Hematologic Malignancies, Nevada Cancer Institute, 10441 W. Twain Ave., Las Vegas, NV 89135, U.S.A.*

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Basic aspect of CD26/DPPIV
 - 3.1. Distribution
 - 3.2. Structure
 - 3.3. Characterization of DPPIV enzyme
4. Biological aspect of CD26/DPPIV and immune regulation
 - 4.1. CD26 and T cell function
 - 4.2. CD26 and other immune cells
5. Molecular aspect of CD26/DPPIV and T cell regulation
 - 5.1. Interacting proteins or cell structure
 - 5.2. T-cell costimulatory signaling via CD26
6. Clinical aspect of CD26 and immune disorders
 - 6.1. Rheumatoid arthritis
 - 6.2. Autoimmune diseases
 - 6.3. Graft-versus-host disease
7. Summary and perspective
8. Acknowledgement
9. References

1. ABSTRACT

CD26 is a 110 kDa surface glycoprotein with intrinsic dipeptidyl peptidase IV (DPPIV, EC 3.4.14.5) activity that is expressed on numerous cell types and has a multitude of biological functions. CD26 role in immune regulation has been extensively characterized, with recent findings elucidating its linkage with signaling pathways and structures involved in T-lymphocyte activation as well as antigen presenting cell (APC)-T-cell interaction. In this paper, we will review emerging data on CD26-mediated T-cell costimulation, suggesting that CD26 may be an appropriate therapeutic target for the treatment of immune disorders. However, the identity of its putative natural ligand had not yet been clearly elucidated. Recently, using protein engineering and proteomic approach, we have recently characterized the putative costimulatory ligand for CD26 in T-cells and the proximal signaling events directly associated with the cytoplasmic region of CD26 in CD26-associated T-cell costimulation, processes that are independent of the CD28 costimulatory pathway. Our work therefore presents novel findings that contribute to the area of T-cell costimulation and signal transduction.

2. INTRODUCTION

CD26 is a 110-kDa cell surface glycoprotein with known dipeptidyl peptidase IV (DPPIV, EC3.4.14.5) activity in its extracellular domain (1-3), capable of cleaving amino-terminal dipeptides with either L-proline or L-alanine at the penultimate position (3). CD26 activity is dependent on cell type and the microenvironment, which influence its multiple biological roles (4-7). CD26 plays an important role in immunology, autoimmunity, diabetes and cancer. Interacting directly with various other cell surface and intracellular molecules, CD26 can regulate receptor specificity and the function of various chemokines and cytokines via its DPPIV activity.

In this review, we summarize current knowledge of the molecular mechanisms of CD26-mediated T-cell costimulation, focusing particularly on CD26 role in cellular pathways and programs associate with human immune regulation. In addition, we describe our recent work that identified a costimulatory ligand for CD26, which had been called “a phantom molecule” since its putative costimulatory ligand had not been previously




Figure 1. Schematic diagram of human CD26 structure. See text for detail.

characterized. We also discuss our data elucidating the proximal signaling events associated with CD26-mediated T-cell costimulation. Finally, we discuss CD26 involvement in various pathophysiologic states, and its suitability as a potential therapeutic target in selected immune diseases.

3. BASIC ASPECT OF CD26/DPPIV

3.1. Distribution

CD26 was originally described in 1966 as an enzyme with intrinsic DPPIV activity (8). DPPIV was later found to be the same as CD26, which is a 110 kDa extracellular membrane-bound glycoprotein that is expressed on many tissues. The amino acid sequence of human CD26 shares approximately 85% homology with the rat DPPIV enzyme and the mouse thymocyte activation molecule (THAM), the mouse homologue of human CD26 (3, 9). CD26 knockout (CD26-KO) mice with C57BL/6 background display an apparently normal phenotype (10). However, the percentage of CD4⁺T-cells is lower in the spleen lymphocyte population of CD26-KO mice than CD26-positive wild-type mice. After immunization of mice with pokeweed mitogen (PWM) *in vivo*, serum levels of total IgG, IgG1, IgG2a and IgE were markedly decreased in CD26-KO mice than those in wild-type mice. Moreover, IL-4 and IL-2 level in sera of CD26-KO mice were decreased and production of interferon-gamma (IFN- γ) was delayed in response to PWM immunization. These results indicate that CD26 helps to regulate the development, maturation and migration of CD4⁺T-cells, cytokine secretion, T-cell-dependent antibody production and immunoglobulin isotype switching of B cells. On the other hand, Abbott *et al.*, found two transcripts of human CD26 (4.2 and 2.8 kbp), both of which were expressed at high levels in the lung and liver (11). Other organs expressing CD26 include: brain, endothelium, heart, intestine, kidney, liver, lung, skeletal muscle, pancreas, placenta, and lymphocytes (11-15). Originally characterized as a T cell differentiation antigen, CD26 is preferentially expressed on a specific population of T lymphocytes, the subset of CD4⁺CD45RO⁺ memory T cells, and is upregulated following T cell activation (15). Besides being a marker of T cell activation, CD26 is also associated with T cell signal transduction processes as a costimulatory molecule (5-7). Since the 1970s, DPPIV-like

activity has been also reported in human serum. Following the identification of the ADA-binding protein in plasma as CD26, soluble form of CD26 protein was characterized in the serum and seminal fluids (16, 17).

3.2. Structure

CD26 is a 110 kDa cell-surface glycoprotein that belongs to the serine protease family, which is characterized by the Ser-Asp-His catalytic triad in the C-terminal region. CD26/DPPIV is a member of a complex gene family, many of which also cleave structurally related peptides (18). These include: prolyl endopeptidase (PEP), acylaminoacyl peptidase (ACPH), CD26/DPPIV, fibroblast activation protein (FAP), DPP8, DPP9, DPP10, and DPPX (18, 19). The N-terminus contains the consensus sequence (DW(V/L)YEEE), with the first two Glu (E) amino acids in this sequence being necessary for enzyme activity, while the C-terminus is also highly conserved (an α/β -hydrolase domain) (20, 21). As shown in Figure 1, human CD26 is composed of 766 amino acids, including a short cytoplasmic domain of 6 amino acids, a transmembrane region of 24 amino acids, and an extracellular domain with dipeptidyl peptidase activity which selectively removes the N-terminal dipeptide from peptides with proline or alanine at the penultimate position (3). The amino acid sequence of human CD26 shares approximately 85% homology with the rat DPPIV enzyme and the mouse thymocyte activation molecule (THAM), the mouse homologue of human CD26 (22). The crystal structure of recombinant human CD26 was determined in the dimeric state at 2.5Å resolution with the DPPIV inhibitor Valine-pyrrolidide (23). The catalytic site (Ser630-Asp708-His740) is located in a large cavity (also called a central tunnel), formed between the α/β -hydrolase domain and eight-bladed β -propeller domain, which contains the consensus sequence (DW(V/L)YEE), that is conserved in S9B protease (20, 23). Single amino acid point mutation in the β -propeller motif identified Glu205 and Glu206 as essential for DPPIV enzyme activity (20), and the central tunnel and α/β -hydrolase domains both participate in DPPIV inhibitor binding (24, 25). The amino acids lining the opening to the catalytic site pocket control substrate specificity (26). Single amino acid point mutation at His750 residue is responsible for dimerization (27). As described below, a central tunnel, DPPIV enzyme pocket and dimerization site are all necessary for caveolin-1 binding, which is found to be the costimulatory ligand for human CD26 (28, 29).

3.3. Characterization of DPPIV enzyme

DPPIV is a serine protease that cleaves dipeptides from the N-terminus of peptides (3). The enzymatic activity of CD26 appears to be very important in enhancing cellular responses to external stimuli. For example, Jurkat cells transfected with wild type CD26 consistently demonstrate greater activation than parental CD26 negative Jurkat or cells transfected with CD26 mutated at the DPPIV enzymatic site (30). Moreover, we have shown that exogenous recombinant soluble CD26 (rsCD26) with DPPIV enzyme activity enhances the proliferative response of peripheral blood lymphocytes (PBLs) to stimulation with the soluble antigen tetanus toxoid (TT) (31). This enhancing effect of rsCD26 was not

observed with mutant rsCD26 lacking DPPIV enzyme activity (31). Although the precise mechanism underlying the enhancing effect of DPPIV enzyme activity has not yet been elucidated, one possible explanation for the role of DPPIV enzyme activity in T-cell activation is its binding activity to the putative ligand caveolin-1 (28, 29).

Possible substrates of CD26/DPPIV include several critical cytokines and chemokines (32). Activity of RANTES (regulated on activation, normal T cell expressed and secreted; CCL5) is altered by the enzymatic cleavage of DPPIV, as CD26/DPPIV-processed RANTES affects important activities such as those implicated in monocyte chemotaxis and HIV-1 infection (33, 34). Other important chemokines that appear to be substrates of DPPIV enzymatic activity include eotaxin (CCL11), macrophage-derived chemokine (MDC) (CCL22), interferon inducible chemokines (CXCL10), and other chemokines involved in the inhibition of HIV infection (34). In addition, recent work showed that CD26 plays an important role in the mobilization of hematopoietic stem cell (HSC) and hematopoietic progenitor cells (HPC) induced by granulocyte colony-stimulating factor (G-CSF) (35). One of the substrates of CD26/DPPIV is CXCL12 (SDF-1 α , stromal cell-derived factor 1 α), an important chemokine that serves as a chemoattractant for HSC/HPC (36, 37). It has been shown that CXCL12 can be selectively truncated *in vitro* by CD26/DPPIV, and the truncated molecule lacks the ability to induce migration of hematopoietic cells isolated from mouse bone marrow. Furthermore, treatment of mice with CD26/DPPIV inhibitors during the process of G-CSF mobilization results in a significant increase in the number of mobilized HPC (35, 36). An exciting development regarding DPPIV involves its role in glucose metabolism, as inhibition of endogenous glucagon-like peptide 1 (GLP-1) degradation by reducing DPPIV activity is an alternative strategy for improving the incretin action of GLP-1 *in vivo* and regulating glucose levels (reviewed in (19)). The first oral selective DPPIV inhibitor was approved by the Food and Drug Administration (FDA) in October 2006, and additional DPPIV inhibitors are under review by FDA for clinical use (19, 38). More selective small molecule inhibitors of DPPIV are currently being investigated in clinical trials for the treatment of impaired glucose tolerance and type 2 diabetes (19, 39).

4. BIOLOGICAL ASPECT OF CD26/DPPIV AND T-CELL REGULATION

4.1. CD26 and T-cell function

While CD26 expression is enhanced following activation of resting T-cells, CD4+CD26^{high} T-cells respond maximally to recall antigens such as tetanus toxoid (TT) (15). Crosslinking of CD26 and CD3 with solid-phase immobilized monoclonal antibodies (mAbs) can induce T-cell costimulation and IL-2 production by CD26+T-cells (3, 15). In addition, anti-CD26 antibody treatment of T-cells enhances tyrosine phosphorylation of signaling molecules such as CD3- ζ and p56^{lck} (40, 41). High CD26 cell surface expression is correlated with the production of T_H1-type cytokines such as IFN- γ , and CD26

expression is induced by stimuli that favor the development of the T_H1 response (42-44). CD26+T-helper cells stimulate antibody synthesis in B-cells and activate MHC-restricted cytotoxic T-cells (15, 45). Moreover, previous reports showed that CD26+ T cells exhibit strong migratory ability through endothelial cells, and are present at high levels in the rheumatoid synovium and the synovial fluids (46-49). CD26 may have therefore an important role in T-cell biology and overall immune function. Moreover, DPPIV activity is required for CD26-mediated T-cell costimulation (30). Jurkat T-cell line (derived from a human T-cell leukemia) transfected with CD26 show greater activation than CD26-negative Jurkat cells or Jurkat cells transfected with CD26 mutated at the DPPIV enzymatic site (serine residue at 630 to alanine) (30). When stimulated by anti-CD3 and anti-CD26 antibodies or the combination of anti-CD3 and phorbol esters, the wild type CD26 (DPPIV containing) transfected Jurkat cells showed more IL-2 production than the mutant CD26 (DPPIV deficient) or vector-only control transfected cells. In addition, DPPIV activity can change T-cell response to a variety of external stimuli through CD26 and/or the CD3/TCR complex to regulate IL-2 production. The DPPIV activity of CD26 is therefore important in enhancing cell activation in response to external stimuli (50). We recently identified a costimulatory ligand for CD26, with its binding to CD26 being dependent on the DPPIV enzyme pocket (29, 51). This topic will be discussed in more detail in the following section.

4.2. CD26 and other immune cells

It has been reported that 0-5% of freshly isolated CD20+B cells do express the CD26 antigen (52). Following stimulation with PMA or *Streptococcus aureus* protein, the fraction of CD26-positive cells increased to 51%. Interestingly, induction of CD26 expression on B cells from patients with combined variable immunodeficiency occurs in a manner similar to the B-cells from healthy donors. Meanwhile, CD26 is not expressed or is found only at low levels on monocytes of healthy adult (53). Flow cytometric analysis of dendritic antigen-presenting cells (DC) generated from peripheral blood of normal donors in the presence of granulocyte/macrophage colony-stimulating factor and IL-4 revealed intermediate levels of CD26 during a 2-week culture period (54). While these findings suggest that CD26 may also be an activation marker for B-cells and APC, its precise role in these cells remains to be elucidated.

Meanwhile, only a small fraction of peripheral NK cells was found to express CD26. Using K562 as target cells, Madueno *et al.* analyzed the lytic capacity of NK cells stimulated with different anti-CD26 mAbs or following separation into CD26+ and CD26- subsets, and observed no detectable difference in the chromium released by the target cells (55). These investigators also evaluated redirected lysis through CD16 by arming both CD26+ and CD26- effector cells with an anti-CD16 antibody, and demonstrated that CD26- cells exhibited significantly less CD16-dependent lysis than CD26+ cells. These results indicate that CD26 is related to CD16-dependent lysis but not to NK cytotoxicity, which may be mediated through




Figure 2. Model for CD26-caveolin-1 interaction leading to upregulation of CD86. (1) Caveolin-1 in monocytes (APC) resides at the inner membrane in the presence or absence of Tollip and IRAK-1. After uptake of tetanus toxoid into APC via caveolae, some population of caveolin-1 is exposed on the outer cell surface of TT-loaded APC (MHC-II + peptide). Migration of CD26+ antigen-specific memory T-cells to areas of antigen-loaded APC results in contact with TT antigen-presenting APC, leading to the association of CD26 and caveolin-1. Aggregation of caveolin-1 in the contact area occurs, presumably by homooligomerization (via its residues 61-101), followed by its phosphorylation. (2) Phosphorylated caveolin-1 dissociates complexed Tollip and IRAK-1, presumably due to conformational changes, and IRAK-1 is then phosphorylated in the cytosol. (3) After IRAK-1 is phosphorylated, NF- κ B is activated to lead to upregulation of CD86. C2, Protein kinase C conserved region 2; CUE, Coupling of ubiquitin-conjugation to endoplasmic reticulum degradation domain; DD, death domain; KD, kinase domain, and CT, C-terminal domain.

protein tyrosine phosphorylation. On the other hand, Shingu *et al.* found that NK cell cytotoxicity against breast adenocarcinoma cells was decreased in CD26 mutant rats (DPPIV-deficient and reduced CD26 surface expression), suggesting that DPPIV activity was associated with NK cytotoxicity (56).

We recently identified caveolin-1 in APC as a binding protein for CD26 and demonstrated that CD26 on activated memory T-cells directly faces caveolin-1 on TT-loaded monocytes in the contact area, which was revealed as the immunological synapse for T-cell-APC interaction (29). Moreover, we showed that residues 201 to 211 of CD26 along with the serine catalytic site at residue 630, which constitute a pocket structure of CD26/DPPIV, contribute to binding to caveolin-1 scaffolding domain (29). More recently, we demonstrated that caveolin-1 binds to Tollip (Toll-interacting protein) and IRAK-1 (interleukin-1 receptor associated serine/threonine kinase 1) in the membrane of tetanus toxoid-loaded monocytes and that following exogenous CD26 stimulation, Tollip and IRAK-1 disengage from caveolin-1, with IRAK-1 being subsequently phosphorylated to upregulate CD86 expression (51). It is conceivable that the interaction of CD26 with caveolin-1 on antigen-loaded monocytes results in CD86 upregulation, therefore enhancing the subsequent interaction of CD86 and CD28 on T-cells to induce antigen-specific T-cell proliferation and activation (Figure 2).

5. MOLECULAR ASPECT OF CD26/DPPIV AND T-CELL REGULATION

5.1. Interacting proteins and cell structure

Many reports have hitherto showed that CD26 interacts with several molecules playing important roles in T-cell function (57). CD26 physically binds with adenosine deaminase (ADA), an enzyme that plays a key role in the development and function of lymphoid tissues (58-60). ADA is essential for purine metabolism, with the loss of ADA leading to a clinical syndrome characterized by severe immunodeficiency (61). When the ADA inhibitor pentostatin was used in the treatment of recurrent T cell lymphomas, a significant reduction in circulating CD26+ T-cells was observed in treated patients (62). This finding is consistent with the fact that there is a physical association between CD26 and ADA on the surface of T lymphocytes.

Mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF-IIR) binds CD26 via M6P residues in the carbohydrate moiety of CD26 (63), an interaction that is important for CD26-mediated T-cell activation and T-cell migration (63, 64). Furthermore, CD26 internalization in T-cell can be mediated by M6P/IGF-IIR (63), with CD26 internalization being associated with increasing levels of CD26 mannose 6-phosphorylation following T cell activation.

CD26 also interacts with CD45RO, a tyrosine phosphatase with a critical role in T cell signal transduction, at lipid rafts in peripheral blood T lymphocytes to modify cellular signaling events (65, 66). A lipid raft is a cholesterol-rich microdomain in cell membrane, which plays an important role in signal transduction in T-cell regulation (67, 68). CD26 interaction with lipid rafts in peripheral blood T-cells influences key cellular signaling events (65, 66). Non-activated peripheral blood T-cells treated with the anti-CD26 mAb 1F7

increased CD26 recruitment to lipid rafts, resulting in increased tyrosine phosphorylation of c-Cbl, Zap70, Erk1/2, p56^{lck}, and TCR- ζ (65). Interestingly, CD26 is associated with CD45 RA outside of lipid rafts in cord blood T cells, and the strong physical linkage of CD26 and CD45 RA may be responsible for the attenuation of cord blood T-cell activation signaling through CD26, which may in turn result in immature immune response and the relatively low incidence of severe graft-versus-host disease (GVHD) in cord blood transplantation (69).

5.2. T-cell costimulatory signaling via CD26

We demonstrated that CD26 binds to caveolin-1 on APC, and that residues 201 to 211 of CD26 along with the serine catalytic site at residue 630, which constitute a pocket structure of CD26/DPPIV, contribute to binding to the caveolin-1 scaffolding domain (29). This region in CD26 contains a caveolin-binding domain (CBD) (Φ X Φ XXXX Φ XX Φ ; Φ and X depict aromatic residue and any amino acid, respectively), specifically WYEEVFVSAY in CD26 (3, 70). These observations strongly support the notion that DPPIV enzyme activity is necessary to exert T-cell costimulatory activation via CD26 as demonstrated in our previous report using CD26 specific mAbs (30). To examine the binding of caveolin-1 to CD26 in T-cells, we made soluble Fc fusion proteins containing the N-terminal domain of caveolin-1 (NT-Fc), and found that NT-Fc binds specifically to CD26 to induce T-cell proliferation in the presence of TCR/CD3 costimulation (28). Moreover, the binding affinity between caveolin-1 and CD26 ($K_d \sim 2 \times 10^{-5}$ M) as determined by the BIAcore system is comparable to that of other costimulatory molecules with important roles in immune responses and their associated ligands, such as CD2-CD5 ($K_d \sim 10^{-6}$ M), CD80-CD28 ($K_d \sim 10^{-7}$ M) and CD86-CD28 ($K_d \sim 10^{-6}$ M) (71-73). Until now, CD26-mediated T-cell costimulation was performed using anti-CD26 mAbs, resulting in various CD26-related functions (4, 6, 7, 74). Assuming that the affinity between antigen and antibody is higher ($K_d \sim 10^{-9}$ M) than that of a ligand-receptor system, and that ligand-specific conformations are capable of differentially activating distinct signaling partners (75), ligand-dependent pathways may be predicted to have different signals associated with the antigen-antibody system and ligand-receptor system.

The precise proximal signaling pathway of CD26 has not yet been identified, particularly in view of the fact that its cytoplasmic tail of CD26 contains only 6 amino acid residues without a common signaling motif structure. Moreover, it has been unclear whether the short cytoplasmic tail is responsible for signal transduction associated with CD26-mediated costimulation. Using recombinant CD26-CD10 chimeric receptor, we showed that the cytoplasmic tail of CD26 is indeed responsible for T-cell costimulation induced by anti-CD3 plus caveolin-1 (28). Furthermore, to explore the proximal signaling molecules interacting with the cytoplasmic tail of dimeric CD26, we used proteomic analyses with Fc fusion proteins containing the cytoplasmic amino acid residues of CD26 to identify that CARMA1 binds to the cytoplasmic tail of dimeric CD26 (28). We further demonstrated that a PDZ

domain in CARMA1 is necessary for binding to CD26. The importance of CARMA1 in CD26-mediated costimulation is also shown by rescue experiments using the CARMA1-deficient Jurkat T-cell line JPM50.6 (28). CARMA1, containing CARD and MAGUK domains, plays an essential role in the NF- κ B activation and IL-2 expression induced by CD3-CD28 or CD28-PMA stimulation (76, 77). Following its phosphorylation, CARMA1 functions as a signaling intermediate downstream of PKC θ and upstream of IKK in the TCR signaling transduction pathway leading to NF- κ B activation (78, 79). We also showed that dimeric CD26, but not monomeric CD26, binds to CARMA1 (28). CD26/DDPPIV is reported to exist as homodimers, a structural organization which allows access of substrates to DPPIV catalytic activity (23, 27). Although DPPIV activity is crucial for CD26-mediated T-cell costimulation (30, 31), the exact role played by DPPIV in this process is unclear. Our recent study showed that the enzymatic pocket structure of the DPPIV catalytic site is necessary for binding of CD26 to caveolin-1, leading to the upregulation of CD86 expression on APC (29, 51). More recently, we found that monomeric CD26 H750E, which has a 300-fold decrease in catalytic activity (27), does not bind to CARMA1, resulting in the loss of CD26-mediated T-cell costimulation by anti-CD3 plus caveolin-1 (28). Therefore, dimerization of CD26 is not only necessary for binding to caveolin-1, but also serves as a scaffolding structure for the cytoplasmic signaling molecule CARMA1. The precise binding position of CARMA1 in the cytoplasmic domain of CD26 remains to be elucidated in future studies, since PDZ domains bind primarily to specific C-terminal motifs (X-S/T-X-V/L; X depicts any amino acids) or internal target motifs as well as other PDZ domains (80).

Based upon the above studies, we propose the following model to explain the sequence of events leading from CD26-CD3 costimulation to NF- κ B activation (Figure 3). In CD3-CD26 costimulation, TCR engagement by peptide-loaded MHC class II presented on APC activates PI3K via phosphorylation of ITAMs (immunoreceptor tyrosine-based activation motifs) in TCR, leading the recruitment of PKC θ and IKK complex in lipid rafts (77, 81-83). Concomitantly, CD26 ligation by caveolin-1 on APC recruits CD26-interacting CARMA1 to lipid rafts, resulting in the formation of a CARMA1-Bcl10-MALT1-IKK complex, and this membrane-associated Bcl10 complex then activates IKK through ubiquitination of NEMO (76, 77, 81-84).

6. CLINICAL ASPECT OF CD26 AND IMMUNE DISORDERS

6.1. Rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic, inflammatory autoimmune disease that primarily affects the joints, but also has systemic symptoms. CD26/DDPPIV is overexpressed on T-cells in the peripheral blood and synovial fluid of patients with RA. CD26+ T-cells induce the inflammation and tissue destruction characteristic of RA by migrating to and being active in the rheumatoid synovium (48). Cordera *et al.* studied IL-12, IL-15, soluble




Figure 3. A model for signaling by TCR and CD26 costimulation. Stimulation of cells through TCR complexes leads to phosphorylation of cytoplasmic ITAMs by ligation of peptide-loaded MHC class II (bold arrows) and recruitment and activation of PDK1 with IKKs (gray arrow head), through activation of PI3K and PKC θ . Meanwhile, caveolin-1, the N-terminal extracellular region of which is present on antigen-loaded APC, ligates CD26 which exists as dimers on the cell surface, leading to the recruitment of lipid rafts (gray arrow) and interaction with CARMA1 (gray double-headed arrow). The recruitment of CARMA1 along with CD26 to lipid rafts also engages the CARMA1-Bcl10-PDK1-IKKs complex (black double-headed arrows), leading to activation of the IKK complex (black double-headed arrows), and finally, activation of NF- κ B.

CD26, and ADA serum levels from 35 patients with active and inactive RA as well as those of controls (85). Patients' sera had higher IL-12 and IL-15 levels, and the level of soluble CD26 was inversely correlated with the number of swollen joints. These findings suggest that these cytokines and CD26 are associated with the inflammation and immune activity in RA. Mavropoulos *et al.* found that anti-tumor necrosis factor- α therapy increases DPPIV activity and decreases autoantibodies to the chaperone

protein Bip (GRP78) and phosphoglucose isomerase in 15 patients with RA (86). DPPIV inhibitors inhibit a rat model of rheumatoid arthritis in a dose-dependent manner (87). We described CD26⁺ T-cells infiltrating the rheumatoid synovium using immunohistochemical studies (88). We also noted high expression of caveolin-1 in the rheumatoid synovium vasculature and synoviocytes. These data suggest that the CD26-caveolin-1 upregulation of CD86 on activated monocytes leads to antigen-specific T-

cell activation in rheumatoid arthritis. DPPIV inhibitors may be useful for suppressing the immune system in rheumatoid arthritis and other autoimmune diseases.

6.2. Autoimmune and other immune-mediated disorders

Previous studies have shown that CD26 expression is tightly regulated on human T-cells and that it has a key role in T-cell function (1, 15). CD26 expression on T-cell surface is higher in multiple sclerosis and Graves' disease (89, 90). CD26/DPPIV appears to play a critical role in the effector functions of CD4⁺ T-cells in experimental autoimmune encephalomyelitis systems (91). CD26⁺ T-cells are more sensitive to TCR-mediated activation (92), and CD26 is expressed preferentially on the subset of CD4⁺ helper cells in response to recall antigens (15).

CD26/DPPIV levels in human serum (soluble CD26) have been examined in patients with various medical conditions, such as autoimmune diseases, infectious diseases, and psychiatric disorders (93). To determine the role of soluble CD26 in the pathophysiology of patients with systemic lupus erythematosus (SLE), we measured levels of soluble CD26 and its specific DPPIV activity in serum (94). Serum levels of soluble CD26 and its specific DPPIV activity were significantly decreased in patients with SLE, and were inversely correlated with SLE disease activity index score, but not with clinical variables or clinical subsets of SLE (94). In patients with inflammatory bowel diseases (IBD) such as Crohn's disease or ulcerative colitis, CD26⁺T-cells and DPPIV activity in serum were examined (95, 96). In these studies, the DPPIV activity was reduced in patients with IBD, and the number of CD25⁺CD26⁺ T-cells in the peripheral blood was increased in patients with IBD. Taken together, these data indicate that CD26 may be potentially important for the pathophysiology of SLE and IBD, and appears to be useful as a new marker for disease activity in SLE or IBD.

CD4⁺ T-cells in patients with AIDS develop an intrinsic defect in their ability to recognize and respond to recall antigens prior to a detectable reduction in the total number of CD4⁺ T-cells (97, 98). The response to recall antigens is clearly a property of CD4⁺CD26⁺ T-cells, since this is the only helper population known to proliferate in response to soluble antigens, and to induce both MHC-restricted cytotoxic T-cells capable of killing virus-infected target cells and immoglobulin-secreting B-cells (15). In this regard, a selective decrease in CD26⁺ T-cells has been reported in HIV-1-infected individuals prior to a general decrease in CD4⁺ T-cells (99, 100). Moreover, Tat, a regulatory protein encoded by the HIV-1 genome which has been shown to suppress the response of human peripheral T-cells to soluble antigens (101, 102), can bind to CD26 and partially inhibit DPPIV enzyme activity (103). We have shown that the DPPIV enzyme activity of plasma soluble CD26 was low in HIV-1-infected individuals, and was inversely correlated with HIV-1 RNA, and that the *in vitro* addition of recombinant soluble CD26 could enhance purified protein derivative-induced lymphocyte proliferation (104). These results suggest that the specific

DPPIV enzyme activity of plasma soluble CD26 in HIV-1-infected individuals contributes to the immunopathogenesis of HIV infection. Taken together, the above findings suggest that CD26/DPPIV plays an important role in the pathophysiology of autoimmune diseases and other immune-mediated disorders. Moreover, *in vivo* recombinant soluble CD26 supplementation in immunodeficient patients with decreased soluble CD26/DPPIV may be of use in restoring functional immune response.

6.3. Graft-versus-host disease (GVHD)

GVHD remains a major cause of morbidity and mortality in allogeneic stem cell transplantation (alloSCT). In GVHD, mature donor T-cells that accompany the stem cell graft attack recipient tissues, especially the skin, liver, gastrointestinal tract, and lung. Therefore, all patients undergoing alloSCT receive GVHD prophylaxis to impair T-cell function; however, treatment to prevent GVHD can be deleterious since mature donor T-cells play a critical role in mediating reconstitution of the adaptive immune system, especially in adults with diminished thymic function (105). Recipients of alloSCT are thus at great risk for infections, particularly when prolonged immunosuppression is required for treatment of GVHD. Some approaches (e.g., B7-blocking, OX40-blocking, and T-cell depletion by specific antibodies) to promote the positive effects of alloSCT without GVHD have been developed recently in the clinical settings (reviewed in (106)). Although the role of CD26/DPPIV in GVHD needs to be studied in more detail, treatment with a murine antibody against human CD26 was reported to have an effect in patients with steroid-resistant acute GVHD following alloSCT (107, 108). Moreover, we have previously examined the expression of CD26 as well as the reconstitution of CD26-mediated T-cell costimulation via the CD3 and CD2 pathways at various times in patients with CD6-positive T-cell depleted allogeneic bone marrow transplantation (alloBMT) (109). In this study, we found that the percentage of CD26- and CD3-positive cells, as well as the levels of expression of both antigens, was lower than in normal controls during the first 4 months after CD6-depleted alloBMT. Subsequently, the amount of lymphocytes expressing CD3 and CD26 and the quantitative surface expression of CD3 and CD26 were not significantly different in patients and normal controls. Functional studies showed that CD26-mediated T-cell proliferation via the CD3 pathway was considerably improved and almost reached normal levels by 1 year, whereas recovery of CD26-mediated T-cell proliferation via the CD2 pathway was delayed for at least 2 years after CD6-depleted alloBMT. As CD26 involvement in the regulation of human thymocyte activation is restricted preferentially to the CD3 pathway, unlike its involvement with both CD3 and CD2 pathways of peripheral T cells, our results suggest that the different effects of CD26-mediated costimulation via the CD3 and CD2 pathways after CD6-depleted allo-BMT may be a reflection of peripheral T-cell immaturity in those individuals. Taken together, it may be possible that the full therapeutic potential of alloSCT will be realized by approaches that aim to minimize GVHD by targeting CD26-mediated T-cell regulation.

7. SUMMARY AND PERSPECTIVES

Understanding of the molecular mechanisms involved in CD26-mediated T-cell costimulation has been hindered by the lack of specific costimulatory ligand for CD26 and proximal signaling molecules that can be assessed in comparison with those observed in experiments using anti-CD26 mAbs (6). The results presented here provide a starting point to investigate other mechanisms that have been observed in CD26-mediated cellular functions. For example, downstream targets of CARMA1 may emerge as important mediators of CD26-mediated cellular events as well as T-cell costimulation. Moreover, influencing CD26-mediated T-cell costimulation by using caveolin-1-Fc fusion proteins or by inhibiting dimerization with selected small compounds may lead to new therapeutic approaches to treat T_H1-mediated autoimmune diseases such as rheumatoid arthritis, Grave's disease and multiple sclerosis, and alloreaction following transplantation or atherosclerosis, and to induce adjuvant reaction for T_H1-mediated cancer immunotherapy. Of significance is our recent work demonstrating that CD26 on T-cell surface binds to caveolin-1, hence identifying the first endogenously expressed CD26 costimulatory ligand in the immune system. Moreover, the caveolin-1-CD26 interaction results in strong T-cell costimulation as a result of the recruitment of a molecular complex consisting of CARMA1-Bcl10-MALT1-IKK in lipid rafts. Our findings will therefore serve as a foundation for future insights into the regulation of T-cell costimulation via the CD26 molecule.

8. ACKNOWLEDGEMENT

This work was supported by Grant-in-Aid of Ministry of Education, Science, Sports (K.O. and C.M.) and Culture, Ministry of Health, Labor, and Welfare, Japan (C.M.), and by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (C.M.).

9. REFERENCES

1. Fox, D. A., R. E. Hussey, K. A. Fitzgerald, O. Acuto, C. Poole, L. Palley, J. F. Daley, S. F. Schlossman, and E. L. Reinherz. Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. *J Immunol* 133:1250-1256 (1984)
2. Nanus, D. M., D. Engelstein, G. A. Gastl, L. Gluck, M. J. Vidal, M. Morrison, C. L. Finstad, N. H. Bander, and A. P. Albino. Molecular cloning of the human kidney differentiation antigen gp160: human aminopeptidase A. *Proc Natl Acad Sci U S A* 90:7069-7073 (1993)
3. Tanaka, T., D. Camerini, B. Seed, Y. Torimoto, N. H. Dang, J. Kameoka, H. N. Dahlberg, S. F. Schlossman, and C. Morimoto. Cloning and functional expression of the T cell activation antigen CD26. *J Immunol* 149:481-486 (1992)
4. De Meester, I., S. Korom, J. Van Damme, and S. Scharpe. CD26, let it cut or cut it down. *Immunol Today* 20:367-375 (1999)
5. Fleischer, B. CD26: a surface protease involved in T-cell activation. *Immunol Today* 15:180-184 (1994)
6. Morimoto, C., and S. F. Schlossman. The structure and function of CD26 in the T-cell immune response. *Immunol Rev* 161:55-70 (1998)
7. von Bonin, A., J. Huhn, and B. Fleischer. Dipeptidyl-peptidase IV/CD26 on T cells: analysis of an alternative T-cell activation pathway. *Immunol Rev* 161:43-53 (1998)
8. Hopsu-Havu, V. K., and G. G. Glenner. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. *Histochemie. Histochemistry* 7:197-201 (1966)
9. Marguet, D., A. M. Bernard, I. Vivier, D. Darmoul, P. Naquet, and M. Pierres. cDNA cloning for mouse thymocyte-activating molecule. A multifunctional ecto-dipeptidyl peptidase IV (CD26) included in a subgroup of serine proteases. *J Biol Chem* 267:2200-2208 (1992)
10. Yan, S., D. Marguet, J. Dobers, W. Reutter, and H. Fan. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. *Eur J Immunol* 33:1519-1527 (2003)
11. Abbott, C. A., E. Baker, G. R. Sutherland, and G. W. McCaughan. Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. *Immunogenetics* 40:331-338 (1994)
12. Morrison, M. E., S. Vijayasaradhi, D. Engelstein, A. P. Albino, and A. N. Houghton. A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. *J Exp Med* 177:1135-1143 (1993)
13. Stange, T., U. Kettmann, and H. J. Holzhausen. Immunoelectron microscopic demonstration of the membrane proteases aminopeptidase N/CD13 and dipeptidyl peptidase IV/CD26 in normal and neoplastic renal parenchymal tissues and cells. *Eur J Histochem* 44:157-164 (2000)
14. Vahl, T. P., B. W. Paty, B. D. Fuller, R. L. Pigeon, and D. A. D'Alessio. Effects of GLP-1-(7-36)NH₂, GLP-1-(7-37), and GLP-1-(9-36)NH₂ on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. *The Journal of clinical endocrinology and metabolism* 88:1772-1779 (2003)
15. Morimoto, C., Y. Torimoto, G. Levinson, C. E. Rudd, M. Schrieber, N. H. Dang, N. L. Letvin, and S. F. Schlossman. 1F7, a novel cell surface molecule, involved in helper function of CD4 cells. *J Immunol* 143:3430-3439 (1989)
16. Durinx, C., A. M. Lambeir, E. Bosmans, J. B. Falmagne, R. Berghmans, A. Haemers, S. Scharpe, and I. De Meester. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. *Eur J Biochem* 267:5608-5613 (2000)
17. Iwaki-Egawa, S., Y. Watanabe, Y. Kikuya, and Y. Fujimoto. Dipeptidyl peptidase IV from human serum: purification, characterization, and N-terminal amino acid sequence. *J Biochem (Tokyo)* 124:428-433 (1998)
18. Freker, N., L. Wagner, R. Wolf, U. Heiser, T. Hoffmann, J. U. Rahfeld, J. Schade, T. Karl, H. Y. Naim, M. Alfalah, H. U. Demuth, and S. von Horsten. Neuropeptide Y (NPY) cleaving enzymes: structural and functional homologues of dipeptidyl peptidase 4. *Peptides* 28:257-268 (2007)

19. Drucker, D. J. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. *Diabetes care* 30:1335-1343 (2007)
20. Abbott, C. A., G. W. McCaughan, and M. D. Gorrell. Two highly conserved glutamic acid residues in the predicted beta propeller domain of dipeptidyl peptidase IV are required for its enzyme activity. *FEBS Lett* 458:278-284 (1999)
21. Abbott, C. A., D. M. Yu, E. Woollatt, G. R. Sutherland, G. W. McCaughan, and M. D. Gorrell. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. *Eur J Biochem* 267:6140-6150 (2000)
22. Naquet, P., H. R. MacDonald, P. Brekelmans, J. Barbet, S. Marchetto, W. Van Ewijk, and M. Pierres. A novel T cell-activating molecule (THAM) highly expressed on CD4-CD8- murine thymocytes. *J Immunol* 141:4101-4109 (1988)
23. Rasmussen, H. B., S. Branner, F. C. Wiberg, and N. Wagtmann. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. *Nat Struct Biol* 10:19-25 (2003)
24. David, F., A. M. Bernard, M. Pierres, and D. Marguet. Identification of serine 624, aspartic acid 702, and histidine 734 as the catalytic triad residues of mouse dipeptidyl-peptidase IV (CD26) A member of a novel family of nonclassical serine hydrolases. *J Biol Chem* 268:17247-17252 (1993)
25. Hooper, J. D., J. A. Clements, J. P. Quigley, and T. M. Antal. Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. *J Biol Chem* 276:857-860 (2001)
26. Fulop, V., Z. Bocskei, and L. Polgar. Prolyl oligopeptidase: an unusual beta-propeller domain regulates proteolysis. *Cell* 94:161-170 (1998)
27. Chien, C. H., L. H. Huang, C. Y. Chou, Y. S. Chen, Y. S. Han, G. G. Chang, P. H. Liang, and X. Chen. One site mutation disrupts dimer formation in human DPP-IV proteins. *J Biol Chem* 279:52338-52345 (2004)
28. Ohnuma, K., M. Uchiyama, T. Yamochi, K. Nishibashi, O. Hosono, N. Takahashi, S. Kina, H. Tanaka, X. Lin, N. H. Dang, and C. Morimoto. Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1. *J Biol Chem* 282:10117-10131 (2007)
29. Ohnuma, K., T. Yamochi, M. Uchiyama, K. Nishibashi, N. Yoshikawa, N. Shimizu, S. Iwata, H. Tanaka, N. H. Dang, and C. Morimoto. CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1. *Proc Natl Acad Sci U S A* 101:14186-14191 (2004)
30. Tanaka, T., J. Kameoka, A. Yaron, S. F. Schlossman, and C. Morimoto. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. *Proc Natl Acad Sci U S A* 90:4586-4590 (1993)
31. Ohnuma, K., Y. Munakata, T. Ishii, S. Iwata, S. Kobayashi, O. Hosono, H. Kawasaki, N. H. Dang, and C. Morimoto. Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs. *J Immunol* 167:6745-6755 (2001)
32. Boonacker, E., and C. J. Van Noorden. The multifunctional or moonlighting protein CD26/DPPIV. *European journal of cell biology* 82:53-73 (2003)
33. Oravec, T., M. Pall, G. Roderiquez, M. D. Gorrell, M. Ditto, N. Y. Nguyen, R. Boykins, E. Unsworth, and M. A. Norcross. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. *J Exp Med* 186:1865-1872 (1997)
34. Proost, P., S. Struyf, D. Schols, G. Opdenakker, S. Sozzani, P. Allavena, A. Mantovani, K. Augustyns, G. Bal, A. Haemers, A. M. Lambeir, S. Scharpe, J. Van Damme, and I. De Meester. Truncation of macrophage-derived chemokine by CD26/ dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. *J Biol Chem* 274:3988-3993 (1999)
35. Christopherson, K. W., 2nd, G. Hangoc, C. R. Mantel, and H. E. Broxmeyer. Modulation of hematopoietic stem cell homing and engraftment by CD26. *Science* 305:1000-1003 (2004)
36. Christopherson, K. W., S. Cooper, G. Hangoc, and H. E. Broxmeyer. CD26 is essential for normal G-CSF-induced progenitor cell mobilization as determined by CD26-/- mice. *Exp Hematol* 31:1126-1134 (2003)
37. Christopherson, K. W., 2nd, G. Hangoc, and H. E. Broxmeyer. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. *J Immunol* 169:7000-7008 (2002)
38. Amori, R. E., J. Lau, and A. G. Pittas. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. *Jama* 298:194-206 (2007)
39. Wiedeman, P. E., and J. M. Trevillyan. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes. *Curr Opin Investig Drugs* 4:412-420 (2003)
40. Dang, N. H., Y. Torimoto, K. Sugita, J. F. Daley, P. Schow, C. Prado, S. F. Schlossman, and C. Morimoto. Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation. *J Immunol* 145:3963-3971 (1990)
41. Hegen, M., J. Kameoka, R. P. Dong, S. F. Schlossman, and C. Morimoto. Cross-linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen-activated protein kinase. *Immunology* 90:257-264 (1997)
42. Reinhold, D., U. Bank, F. Buhling, U. Lendeckel, J. Faust, K. Neubert, and S. Ansorge. Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells. *Immunology* 91:354-360 (1997)
43. Reinhold, D., T. Kahne, M. Tager, U. Lendeckel, F. Buhling, U. Bank, S. Wrenger, J. Faust, K. Neubert, and S. Ansorge. The effect of anti-CD26 antibodies on DNA synthesis and cytokine production (IL-2, IL-10 and IFN-gamma) depends on enzymatic activity of DP IV/CD26. *Adv Exp Med Biol* 421:149-155 (1997)
44. Willheim, M., C. Ebner, K. Baier, W. Kern, K. Schratlbauer, R. Thien, D. Kraft, H. Breiteneder, W. Reinisch, and O. Scheiner. Cell surface characterization of T lymphocytes and allergen-specific T cell clones:

- correlation of CD26 expression with T(H1) subsets. *J Allergy Clin Immunol* 100:348-355 (1997)
45. Dang, N. H., D. A. Hafler, S. F. Schlossman, and J. B. Breitmeyer. FcR-mediated crosslinking of Ta1 (CDw26) induces human T lymphocyte activation. *Cell Immunol* 125:42-57 (1990)
46. Gerli, R., C. Muscat, A. Bertotto, O. Bistoni, E. Agea, R. Tognellini, G. Fiorucci, M. Cesarotti, and S. Bombardieri. CD26 surface molecule involvement in T cell activation and lymphokine synthesis in rheumatoid and other inflammatory synovitis. *Clin Immunol Immunopathol* 80:31-37 (1996)
47. Iwata, S., N. Yamaguchi, Y. Munakata, H. Ikushima, J. F. Lee, O. Hosono, S. F. Schlossman, and C. Morimoto. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. *Int Immunol* 11:417-426 (1999)
48. Mizokami, A., K. Eguchi, A. Kawakami, H. Ida, Y. Kawabe, T. Tsukada, T. Aoyagi, K. Maeda, C. Morimoto, and S. Nagataki. Increased population of high fluorescence 1F7 (CD26) antigen on T cells in synovial fluid of patients with rheumatoid arthritis. *J Rheumatol* 23:2022-2026 (1996)
49. Muscat, C., A. Bertotto, E. Agea, O. Bistoni, R. Ercolani, R. Tognellini, F. Spinozzi, M. Cesarotti, and R. Gerli. Expression and functional role of 1F7 (CD26) antigen on peripheral blood and synovial fluid T cells in rheumatoid arthritis patients. *Clin Exp Immunol* 98:252-256 (1994)
50. Pro, B., and N. H. Dang. CD26/dipeptidyl peptidase IV and its role in cancer. *Histol Histopathol* 19:1345-1351 (2004)
51. Ohnuma, K., T. Yamochi, M. Uchiyama, K. Nishibashi, S. Iwata, O. Hosono, H. Kawasaki, H. Tanaka, N. H. Dang, and C. Morimoto. CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells. *Mol Cell Biol* 25:7743-7757 (2005)
52. Buhling, F., U. Junker, D. Reinhold, K. Neubert, L. Jager, and S. Ansorge. Functional role of CD26 on human B lymphocytes. *Immunol Lett* 45:47-51 (1995)
53. Stohlawetz, P., P. Hahn, M. Koller, J. Hauer, H. Resch, J. Smolen, and P. Pietschmann. Immunophenotypic characteristics of monocytes in elderly subjects. *Scandinavian journal of immunology* 48:324-326 (1998)
54. Alijagic, S., P. Moller, M. Artuc, K. Jurgovsky, B. M. Czarnetzki, and D. Schadendorf. Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation. *Eur J Immunol* 25:3100-3107 (1995)
55. Madueno, J. A., E. Munoz, V. Blazquez, R. Gonzalez, P. Aparicio, and J. Pena. The CD26 antigen is coupled to protein tyrosine phosphorylation and implicated in CD16-mediated lysis in natural killer cells. *Scandinavian journal of immunology* 37:425-429 (1993)
56. Shingu, K., A. Helfritz, M. Zielinska-Skowronek, D. Meyer-Olson, R. Jacobs, R. E. Schmidt, R. Mentlein, R. Pabst, and S. von Horsten. CD26 expression determines lung metastasis in mutant F344 rats: involvement of NK cell function and soluble CD26. *Cancer Immunol Immunother* 52:546-554 (2003)
57. Thompson, M. A., K. Ohnuma, M. Abe, C. Morimoto, and N. H. Dang. CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders. *Mini reviews in medicinal chemistry* 7:253-273 (2007)
58. Dong, R. P., J. Kameoka, M. Hegen, T. Tanaka, Y. Xu, S. F. Schlossman, and C. Morimoto. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. *J Immunol* 156:1349-1355 (1996)
59. Dong, R. P., K. Tachibana, M. Hegen, Y. Munakata, D. Cho, S. F. Schlossman, and C. Morimoto. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation. *J Immunol* 159:6070-6076 (1997)
60. Kameoka, J., T. Tanaka, Y. Nojima, S. F. Schlossman, and C. Morimoto. Direct association of adenosine deaminase with a T cell activation antigen, CD26. *Science* 261:466-469 (1993)
61. Goldblum, R. M., F. C. Schmalstieg, J. A. Nelson, and G. C. Mills. Adenosine deaminase (ADA) and other enzyme abnormalities in immune deficiency states. *Birth Defects Orig Artic Ser* 14:73-84 (1978)
62. Dang, N. H., F. B. Hagemeister, M. Duvic, J. E. Romaguera, A. Younes, D. Jones, B. Samuels, L. E. Fayad, B. Pro, F. Samaniego, A. Sarris, A. Goy, P. McLaughlin, A. T. Tong, P. L. Walker, L. P. Tiongson, T. L. Smith, Y. O. Huh, C. Morimoto, and M. A. Rodriguez. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. *Oncol Rep* 10:1513-1518 (2003)
63. Ikushima, H., Y. Munakata, T. Ishii, S. Iwata, M. Terashima, H. Tanaka, S. F. Schlossman, and C. Morimoto. Internalization of CD26 by mannose 6-phosphate/insulin-like growth factor II receptor contributes to T cell activation. *Proc Natl Acad Sci U S A* 97:8439-8444 (2000)
64. Ikushima, H., Y. Munakata, S. Iwata, K. Ohnuma, S. Kobayashi, N. H. Dang, and C. Morimoto. Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. *Cell Immunol* 215:106-110 (2002)
65. Ishii, T., K. Ohnuma, A. Murakami, N. Takasawa, S. Kobayashi, N. H. Dang, S. F. Schlossman, and C. Morimoto. CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. *Proc Natl Acad Sci U S A* 98:12138-12143 (2001)
66. Torimoto, Y., N. H. Dang, E. Vivier, T. Tanaka, S. F. Schlossman, and C. Morimoto. Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. *J Immunol* 147:2514-2517 (1991)
67. Simons, K., and E. Ikonen. Functional rafts in cell membranes. *Nature* 387:569-572 (1997)
68. Xavier, R., T. Brennan, Q. Li, C. McCormack, and B. Seed. Membrane compartmentation is required for efficient T cell activation. *Immunity* 8:723-732 (1998)
69. Kobayashi, S., K. Ohnuma, M. Uchiyama, K. Iino, S. Iwata, N. H. Dang, and C. Morimoto. Association of CD26 with CD45RA outside lipid rafts attenuates cord blood T-cell activation. *Blood* 103:1002-1010 (2004)
70. Smart, E. J., G. A. Graf, M. A. McNiven, W. C. Sessa, J. A. Engelman, P. E. Scherer, T. Okamoto, and M. P. Lisanti. Caveolins, liquid-ordered domains, and signal transduction. *Mol Cell Biol* 19:7289-7304 (1999)

71. Collins, A. V., D. W. Brodie, R. J. Gilbert, A. Iaboni, R. Manso-Sancho, B. Walse, D. I. Stuart, P. A. van der Merwe, and S. J. Davis. The interaction properties of costimulatory molecules revisited. *Immunity* 17:201-210 (2002)
72. van der Merwe, P. A., A. N. Barclay, D. W. Mason, E. A. Davies, B. P. Morgan, M. Tone, A. K. Krishnam, C. Ianelli, and S. J. Davis. Human cell-adhesion molecule CD2 binds CD58 (LFA-3) with a very low affinity and an extremely fast dissociation rate but does not bind CD48 or CD59. *Biochemistry* 33:10149-10160 (1994)
73. van der Merwe, P. A., D. L. Bodian, S. Daenke, P. Linsley, and S. J. Davis. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. *J Exp Med* 185:393-403 (1997)
74. Ohnuma, K., T. Ishii, S. Iwata, O. Hosono, H. Kawasaki, M. Uchiyama, H. Tanaka, T. Yamochi, N. H. Dang, and C. Morimoto. G1/S cell cycle arrest provoked in human T cells by antibody to CD26. *Immunology* 107:325-333 (2002)
75. Chen, C. Y., Y. Cordeaux, S. J. Hill, and J. R. King. Modelling of signalling via G-protein coupled receptors: pathway-dependent agonist potency and efficacy. *Bull Math Biol* 65:933-958 (2003)
76. Gaide, O., B. Favier, D. F. Legler, D. Bonnet, B. Brissoni, S. Valitutti, C. Bron, J. Tschopp, and M. Thome. CARMA1 is a critical lipid raft-associated regulator of TCR-induced NF-kappa B activation. *Nat Immunol* 3:836-843 (2002)
77. Wang, D., Y. You, S. M. Case, L. M. McAllister-Lucas, L. Wang, P. S. DiStefano, G. Nunez, J. Bertin, and X. Lin. A requirement for CARMA1 in TCR-induced NF-kappa B activation. *Nat Immunol* 3:830-835 (2002)
78. Lin, X., and D. Wang. The roles of CARMA1, Bcl10, and MALT1 in antigen receptor signaling. *Semin Immunol* 16:429-435 (2004)
79. Thome, M. CARMA1, BCL-10 and MALT1 in lymphocyte development and activation. *Nat Rev Immunol* 4:348-359 (2004)
80. Dimitratos, S. D., D. F. Woods, D. G. Stathakis, and P. J. Bryant. Signaling pathways are focused at specialized regions of the plasma membrane by scaffolding proteins of the MAGUK family. *Bioessays* 21:912-921 (1999)
81. Egawa, T., B. Albrecht, B. Favier, M. J. Sunshine, K. Mirchandani, W. O'Brien, M. Thome, and D. R. Littman. Requirement for CARMA1 in antigen receptor-induced NF-kappa B activation and lymphocyte proliferation. *Curr Biol* 13:1252-1258 (2003)
82. Wang, L., Y. Guo, W. J. Huang, X. Ke, J. L. Poyet, G. A. Manji, S. Merriam, M. A. Glucksmann, P. S. DiStefano, E. S. Alnemri, and J. Bertin. Card10 is a novel caspase recruitment domain/membrane-associated guanylate kinase family member that interacts with BCL10 and activates NF-kappa B. *J Biol Chem* 276:21405-21409 (2001)
83. Zhou, H., I. Wertz, K. O'Rourke, M. Ultsch, S. Seshagiri, M. Eby, W. Xiao, and V. M. Dixit. Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. *Nature* 427:167-171 (2004)
84. Wegener, E., A. Oeckinghaus, N. Papadopoulou, L. Lavitas, M. Schmidt-Suppran, U. Ferch, T. W. Mak, J. Ruland, V. Heissmeyer, and D. Krappmann. Essential role for IkappaB kinase beta in remodeling Carma1-Bcl10-Malt1 complexes upon T cell activation. *Mol Cell* 23:13-23 (2006)
85. Cordero, O. J., F. J. Salgado, A. Mera-Varela, and M. Nogueira. Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis. *Rheumatology international* 21:69-74 (2001)
86. Mavropoulos, J. C., M. Cuchacovich, C. Llanos, J. C. Aguillon, H. Gatica, S. V. Pizzo, and M. Gonzalez-Gronow. Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritis. *J Rheumatol* 32:2116-2124 (2005)
87. Tanaka, S., T. Murakami, H. Horikawa, M. Sugiura, K. Kawashima, and T. Sugita. Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. *International journal of immunopharmacology* 19:15-24 (1997)
88. Ohnuma, K., H. Inoue, M. Uchiyama, T. Yamochi, O. Hosono, N. H. Dang, and C. Morimoto. T-cell activation via CD26 and caveolin-1 in rheumatoid synovium. *Mod Rheumatol* 16:3-13 (2006)
89. Eguchi, K., Y. Ueki, C. Shimomura, T. Otsubo, H. Nakao, K. Migita, A. Kawakami, M. Matsunaga, H. Tezuka, and N. Ishikawa. Increment in the T_H1⁺ cells in the peripheral blood and thyroid tissue of patients with Graves' disease. *J Immunol* 142:4233-4240 (1989)
90. Hafler, D. A., D. A. Fox, M. E. Manning, S. F. Schlossman, E. L. Reinherz, and H. L. Weiner. *In vivo* activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. *The New England journal of medicine* 312:1405-1411 (1985)
91. Natarajan, C., and J. J. Bright. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. *J Immunol* 168:6506-6513 (2002)
92. Hafler, D. A., M. Chofflon, D. Benjamin, N. H. Dang, and J. Breitmeyer. Mechanisms of immune memory. T cell activation and CD3 phosphorylation correlates with T_H1 (CDw26) expression. *J Immunol* 142:2590-2596 (1989)
93. Gorrell, M. D., V. Gysbers, and G. W. McCaughan. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. *Scandinavian journal of immunology* 54:249-264 (2001)
94. Kobayashi, H., O. Hosono, T. Mimori, H. Kawasaki, N. H. Dang, H. Tanaka, and C. Morimoto. Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus. *J Rheumatol* 29:1858-1866 (2002)
95. Hildebrandt, M., M. Rose, J. Ruter, A. Salama, H. Monnikes, and B. F. Klapp. Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease. *Scandinavian journal of gastroenterology* 36:1067-1072 (2001)
96. Rose, M., M. Hildebrandt, H. Fliege, S. Seibold, H. Monnikes, and B. F. Klapp. T-cell immune parameters and depression in patients with Crohn's disease. *Journal of clinical gastroenterology* 34:40-48 (2002)
97. Lane, H. C., J. M. Depper, W. C. Greene, G. Whalen, T. A. Waldmann, and A. S. Fauci. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective

defect in soluble antigen recognition. *The New England journal of medicine* 313:79-84 (1985)

98. van Noesel, C. J., R. A. Gruters, F. G. Terpstra, P. T. Schellekens, R. A. van Lier, and F. Miedema. Functional and phenotypic evidence for a selective loss of memory T cells in asymptomatic human immunodeficiency virus-infected men. *J Clin Invest* 86:293-299 (1990)

99. Blazquez, M. V., J. A. Madueno, R. Gonzalez, R. Jurado, W. W. Bachovchin, J. Pena, and E. Munoz. Selective decrease of CD26 expression in T cells from HIV-1-infected individuals. *J Immunol* 149:3073-3077 (1992)

100. Gougeon, M. L., H. Lecoer, C. Callebaut, E. Jacotot, A. Dulioust, R. Roue, L. Montagnier, and A. G. Hovanessian. Selective loss of the CD4⁺/CD26⁺ T-cell subset during HIV infection. *Research in immunology* 147:5-8 (1996)

101. Cullen, B. R. Does HIV-1 Tat induce a change in viral initiation rights? *Cell* 73:417-420 (1993)

102. Viscidi, R. P., K. Mayur, H. M. Lederman, and A. D. Frankel. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. *Science* 246:1606-1608 (1989)

103. Gutheil, W. G., M. Subramanyam, G. R. Flentke, D. G. Sanford, E. Munoz, B. T. Huber, and W. W. Bachovchin. Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity. *Proc Natl Acad Sci U S A* 91:6594-6598 (1994)

104. Hosono, O., T. Homma, H. Kobayashi, Y. Munakata, Y. Nojima, A. Iwamoto, and C. Morimoto. Decreased dipeptidyl peptidase IV enzyme activity of plasma soluble CD26 and its inverse correlation with HIV-1 RNA in HIV-1 infected individuals. *Clinical Immunology* 91:283-295 (1999)

105. Mackall, C. L., and R. E. Gress. Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. *Immunol Rev* 157:61-72 (1997)

106. Shlomchik, W. D. Graft-versus-host disease. *Nat Rev Immunol* 7:340-352 (2007)

107. Bacigalupo, A., G. Corte, D. Ramarli, M. T. van Lint, F. Frassoni, and A. Marmont. Intravenous monoclonal antibody (BT 5/9) for the treatment of acute graft-versus-host disease. *Acta Haematol* 73:185-186 (1985)

108. de Meester, I., S. Scharpe, G. Vanham, E. Bosmans, H. Heyligen, G. Vanhoof, and G. Corte. Antibody binding profile of purified and cell-bound CD26. Designation of BT5/9 and TA5.9 to the CD26 cluster. *Immunobiology* 188:145-158 (1993)

109. Kameoka, J., T. Sato, Y. Torimoto, K. Sugita, R. J. Soiffer, S. F. Schlossman, J. Ritz, and C. Morimoto. Differential CD26-mediated activation of the CD3 and CD2 pathways after CD6-depleted allogeneic bone marrow transplantation. *Blood* 85:1132-1137 (1995)

Abbreviations: ADA: adenosine deaminase; APC: antigen-presenting cells; alloSCT: allogeneic stem cell transplantation; BMT: bone marrow transplantation; CBD: caveolin-binding domain; DPPIV: dipeptidyl peptidase IV; GLP-1: glucagon-like peptide 1; GVHD: graft-versus-host disease; IRAK-1: interleukin-1 receptor associated

serine/threonine kinase 1; M6P/IGF-IIR: mannose 6-phosphate/insulin-like growth factor II receptor; NT-Fc: soluble Fc fusion proteins containing the N-terminal domain of caveolin-1; PMA: pokeweed mitogen; RA: rheumatoid arthritis; rsCD26: recombinant soluble CD26; TT: tetanus toxoid; mAb: monoclonal antibody; Tollip: Toll-interacting protein; TCR: T-cell receptor

Key Words: CD26, DPPIV, caveolin-1, CARMA1, Review

Send correspondence to: Dr. C. Morimoto, Division of Clinical Immunology, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan, Tel: 81-354-495-546, Fax: 81-354-495-448, E-mail: morimoto@ims.u-tokyo.ac.jp

<http://www.bioscience.org/current/vol13.htm>